Name:
Tezepelumab for severe asthma: PATHWAY and NAVIGATOR studies
Description:
Tezepelumab for severe asthma: PATHWAY and NAVIGATOR studies
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/d35f7465-c4e7-486a-9177-ceb13fd853f1/videoscrubberimages/Scrubber_45.jpg
Duration:
T00H01M33S
Embed URL:
https://stream.cadmore.media/player/d35f7465-c4e7-486a-9177-ceb13fd853f1
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/d35f7465-c4e7-486a-9177-ceb13fd853f1/Vjbm-2023-0014 V3.mp4?sv=2019-02-02&sr=c&sig=k3LUOx57DN9FQcjkytsiPwYr5LYygRFNFFh12qBSXnw%3D&st=2024-11-21T18%3A53%3A09Z&se=2024-11-21T20%3A58%3A09Z&sp=r
Upload Date:
2024-05-30T00:00:00.0000000
Transcript:
Language: EN.
Segment:0 .
Severe, uncontrolled asthma is a type of asthma in which symptoms are hard to control – even with optimal management. Asthma attacks are triggered by breathing in airborne particles, such as viruses, bacteria, or allergens. When these particles come into contact with the airway, a protein called TSLP is released. TSLP is one of the first steps in airway inflammation. Tezepelumab is a drug that blocks TSLP.
Blocking a key first step will hopefully decrease inflammation more broadly than other approaches. The PATHWAY and NAVIGATOR studies assessed the safety and efficacy of tezepelumab on top of standard inhaler medications in people with severe asthma. Unlike other studies, they enrolled participants with different disease traits, including with or without allergies and high or low blood inflammatory cells, call eosinophils.
In both studies, tezepelumab reduced the number of severe asthma attacks and increased the volume of air participants could breathe out, compared with placebo. Adverse events were generally similar between the groups. Tezepelumab works in a broad population of people with severe asthma and has an acceptable safety profile. It was approved for people aged 12 or older in the USA, EU, and several other countries without restrictions – meaning that it can be used by people with all types of severe asthma.